Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 1 times since 1990 (0 per year) source: EuropePMC
The European respiratory journal, Volume 3, Issue 8, 1 1 1990, Pages 934-936 An alcoholic with pleural effusion. Girbes AR, Postmus PE, Jansen W, vd Jagt EJ, Kleibeuker JH
Cited 11 times since 1990 (0.3 per year) source: EuropePMC
The American journal of medicine, Volume 89, Issue 2, 1 1 1990, Pages 247-248 Decreased phenytoin level after carboplatin treatment. Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-Reiche H, Smit EF, Postmus PE
Cited 1 times since 1990 (0 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 8, Issue 7, 1 1 1990, Pages 1281 Etoposide and mesothelioma. Smit EF, Berendsen HH, Postmus PE
Cited 1 times since 1990 (0 per year) source: EuropePMC
Thorax, Volume 45, Issue 7, 1 1 1990, Pages 563-564 Massive pleural effusion due to pancreatic pseudocyst. Girbes AR, Postmus PE, Jansen W, vd Jagt EJ, Kleibeuker JH
Four patients with massive pleural effusions due to pancreatic pseudocysts who were initially treated conservatively with percutaneous pleural drainage are described. In two patients the pleural effusions and the pancreatic pseudocysts disappeared, but two required surgery, in one case because conservative treatment failed and in the other at a later date for a recurrent pancreatic pseudocyst. Abstract
The European respiratory journal, Volume 3, Issue 7, 1 1 1990, Pages 833-836 Bilateral pleural effusion due to malignant mesothelioma, diagnosed by means of immunostaining. Mannes GP, Gouw AS, Postmus PE
We report a patient who presented himself with a bilateral pleural effusion. Histology proved that this was caused by a malignant pleural mesothelioma. Immunostaining and DNA-flow cytometry confirmed the diagnosis. The usefulness of these rather new diagnostic techniques is discussed. Abstract
Cited 24 times since 1990 (0.7 per year) source: EuropePMC
Seminars in oncology, Volume 17, Issue 1 Suppl 2, 1 1 1990, Pages 49-53 Single-agent oral etoposide for elderly small cell lung cancer patients. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE
Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rates. However, treatment of these patients is often indicated, if not demanded. Etoposide is among the most active agents for the treatment of SCLC; both oral (PO) and intravenous prep... Abstract
Cited 41 times since 1990 (1.2 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 26, Issue 9, 1 1 1990, Pages 932-936 Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Biesma B, de Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC, Stern AC, Vellenga E
30 patients with chemotherapy-related leukopenia (white cells 1.0 x 10(9)/l or lower) and fever (temperature 38.5 degrees C or higher) were treated in a double-blind randomised trial with standard antibiotics and 7 days of intravenously administered recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, 2.8 micrograms/kg per day) or placebo. GM-CSF administration resulted in a faster percentage increase of peripheral neutrophil count after 2 and 3 days of treatment, except i... Abstract
Cited 58 times since 1989 (1.7 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 7, Issue 11, 1 1 1989, Pages 1614-1620 Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, The H
In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures. Similar features can be recognized only in a minority of non-SCLC tumors. During a period of 30 months, all diagnostic non-SCLC biopsies (141 cases) were prospectively analysed for the presence of markers indicative for neuroendocrine differentiation. In 31% of all cases, such a presence... Abstract
Cited 2 times since 1989 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 2, Issue 9, 1 1 1989, Pages 853-855 Treatment of post pneumonectomy pleural empyema by open window thoracostomy. Postmus PE, Kerstjens JM, de Boer WJ, Homan van der Heide JN, Koëter GH
In 13 patients an open window thoracostomy (OWT) was performed for post pneumonectomy pleural empyema. The operation, and life with an OWT cavity, were tolerated well. Early closure of an OWT is not advisable because of a high chance of recurrence of the infection and, in lung cancer patients also the risk of tumour relapse within two years after tumour surgery. Abstract
Chest, Volume 96, Issue 4, 1 1 1989, Pages 917-918 Adam's antipole. Links TP, Postmus PE
Nederlands tijdschrift voor geneeskunde, Volume 133, Issue 38, 1 1 1989, Pages 1876-1879 [Clinical lung transplantation; possibilities, difficulties and trends]. Oosterhoff Y, Postma DS, de Boer WJ, Postmus PE, Prop J, Wildevuur CR
Cited 44 times since 1989 (1.3 per year) source: EuropePMC
Thorax, Volume 44, Issue 8, 1 1 1989, Pages 631-633 A phase II study of oral etoposide in elderly patients with small cell lung cancer. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxici... Abstract
Cited 2 times since 1989 (0.1 per year) source: EuropePMC
Chest, Volume 96, Issue 2, 1 1 1989, Pages 391-392 Dextrocardia? Mannes GP, van der Jagt EJ, Wouters B, Postmus PE
Cited 26 times since 1989 (0.7 per year) source: EuropePMC
British journal of cancer, Volume 60, Issue 1, 1 1 1989, Pages 116-120 Acute and cumulative effects of carboplatin on renal function. Sleijfer DT, Smit EF, Meijer S, Mulder NH, Postmus PE
Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by ex... Abstract
The European respiratory journal, Volume 2, Issue 7, 1 1 1989, Pages 688-689 Fatal pneumonia in a patient with a superior mediastinal mass. Boersma WG, Nikkels PG, van der Jagt EJ, Postmus PE
Cited 1 times since 1989 (0 per year) source: EuropePMC
Chest, Volume 95, Issue 6, 1 1 1989, Pages 1331-1332 A pyrrhic victory in small cell lung cancer. Russchen GH, Limburg AJ, Postmus PE
Cited 1 times since 1989 (0 per year) source: EuropePMC
Annals of internal medicine, Volume 110, Issue 12, 1 1 1989, Pages 1034 Carboplatin and renal function. Smit EF, Sleijfer DT, Meijer S, Mulder NH, Postmus PE
Cited 5 times since 1989 (0.1 per year) source: EuropePMC
Lancet (London, England), Volume 1, Issue 8640, 1 1 1989, Pages 735-736 Transfusion associated graft-versus-host disease in autologous bone marrow transplantation. Mulder NH, Elema JD, Postmus PE
Chest, Volume 95, Issue 3, 1 1 1989, Pages 709-710 Oral etoposide for a 95-year-old patient with small cell lung cancer. Smit EF, Sleijfer DT, Postmus PE
Cited 4 times since 1989 (0.1 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 25, Issue 2, 1 1 1989, Pages 377-378 High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer. Postmus PE, Haaxma-Reiche H, Berendsen HH, Sleijfer DT